TABLE 2.
Results From Univariable and Multivariable Analysis of Factors Associated With Survival
| Univariable Analysis | Multivariable Analysis | |||||
|---|---|---|---|---|---|---|
| TR | 95% CI | P | TR | 95% CI | P | |
| Sex | ||||||
| Male | Reference | Reference | ||||
| Female | 1.08 | (0.97–1.21) | 0.153 | 1.05 | (0.95–1.17) | 0.343 |
| Procedure type | ||||||
| Proximal pancreatectomy | Reference | Reference | ||||
| Distal pancreatectomy | 1.32 | (0.80–2.17) | 0.272 | 1.35 | (0.83–2.18) | 0.222 |
| Radical antegrade pancreaticosplenectomy | 0.81 | (0.40–1.63) | 0.553 | 0.81 | (0.41–1.59) | 0.536 |
| Other partial pancreatectomy | 1.10 | (0.62–1.92) | 0.748 | 1.16 | (0.67–1.99) | 0.598 |
| Total pancreatectomy | 1.09 | (0.63–1.89) | 0.756 | 1.17 | (0.69–1.99) | 0.567 |
| Whipple | 1.07 | (0.66–1.74) | 0.789 | 1.14 | (0.71–1.83) | 0.579 |
| Age | 1.00 | (1.00–1.01) | 0.153 | 1.01 | (1.00–1.02) | 0.006 |
| Nodal Involvement | 0.63 | (0.57–0.71) | <0.001 | 0.73 | (0.63–0.85) | <0.001 |
| Initial complications | ||||||
| None | Reference | Reference | ||||
| 1 | 0.93 | (0.81–1.06) | 0.272 | 0.93 | (0.82–1.06) | 0.288 |
| 2 or more | 0.63 | (0.44–0.90) | 0.012 | 0.62 | (0.45–0.88) | 0.006 |
| Charlson co-morbidity index | ||||||
| ≤2 | Reference | Reference | ||||
| >2 | 0.67 | (0.60–0.74) | <0.001 | 0.80 | (0.69–0.93) | 0.003 |
| Neoadjuvant chemotherapy | 0.70 | (0.60–0.81) | <0.001 | 0.82 | (0.68–1.00) | 0.055 |
| Neoadjuvant radiation | 0.69 | (0.58–0.82) | <0.001 | 0.76 | (0.61–0.95) | 0.016 |
| Chemotherapy | ||||||
| Gemcitabine | 0.89 | (0.79–1.00) | 0.055 | 1.23 | (0.93–1.64) | 0.153 |
| Gemcitabine + nab-paclitaxel | 1.09 | (0.89–1.33) | 0.399 | 1.26 | (1.02–1.57) | 0.035 |
| FOLFIRINOX | 0.87 | (0.74–1.03) | 0.108 | 1.09 | (0.89–1.33) | 0.397 |
| Oxaliplatin | 0.94 | (0.74–1.18) | 0.578 | 0.99 | (0.79–1.25) | 0.937 |
| Capecitabine | 1.00 | (0.86–1.17) | 0.968 | 1.10 | (0.94–1.29) | 0.235 |
| Erlotinib | 0.73 | (0.53–0.99) | 0.044 | 0.79 | (0.58–1.07) | 0.126 |
| Radiation therapy | ||||||
| Radiation without concurrent infusion | 0.88 | (0.78–0.99) | 0.036 | 1.14 | (0.97–1.33) | 0.103 |
| Radiation with 5-FU | 0.81 | (0.72–0.91) | 0.001 | 0.83 | (0.71–0.98) | 0.030 |
| Radiation with gemcitabine | 0.86 | (0.76–0.97) | 0.014 | 0.79 | (0.58–1.08) | 0.141 |
| Adjuvant chemotherapy | 0.89 | (0.79–1.01) | 0.068 | |||
| Adjuvant radiation therapy | 0.99 | (0.87–1.13) | 0.936 | |||
5-FU indicates 5-fluorouracil; CI, confidence interval; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, oxaliplatin; TR, time ratio. For variables used as indicators of ever-receipt of certain chemotherapy or radiation regimens, the reference category is nonreceipt of that chemotherapy or radiation therapy.